CDC Logo Skip Top Nav
 CDC Home PageSearch the CDCHealth Topics A though Z
Skip
Division of Tuberculosis Elimination
About DTBE Upcoming Events Site Map CDC en Espanol Contact Us
 
Skip the Contents menu

Contents

Skip the Resources menu

Resources



U.S. Department of Health and Human Services
 
 

TB Notes Newsletter

Return to TB Notes 2, 2006 Main Menu

This is an archived document. The links and content are no longer being updated.

No. 2, 2006

SURVEILLANCE, EPIDEMIOLOGY, AND OUTBREAK INVESTIGATIONS BRANCH UPDATES

Enhanced Surveillance to Identify Missed Opportunities for TB Prevention in the Foreign-born: Closing the Gap

A CDC-funded study in the United States and Canada that is aimed at closing the gap in TB incidence between native-born and foreign-born persons began in April. Its purposes are to (1) describe the epidemiology of TB in foreign-born persons in the United States and Canada, (2) identify missed opportunities to prevent development and transmission of TB in foreign-born persons, and (3) make recommendations for program improvements at the national, state or provincial, and local levels. To date, study researchers have conducted almost 1,300 of a planned 1,500 interviews with foreign-born persons newly diagnosed with TB.

The study involves all 21 sites of the Tuberculosis Epidemiologic Studies Consortium (TBESC) in 17 states and two Canadian provinces. The TBESC was established in September 2001 to conduct TB research and to strengthen TB public health infrastructure in the United States and Canada. The sites include academic institutions, medical centers, and TB control programs. TBESC has 16 research projects underway.

TBESC selected the epidemiology of TB in foreign-born persons as a top research priority because of its critical importance to TB elimination in the United States and Canada. In the past decade, TB case numbers and rates in North America have dropped faster among native-born persons compared to foreign-born persons. The result has been a growing gap in TB incidence between the two groups. In 2003, the TB rate among foreign-born persons in the United States (23.6 per 100,000) was almost nine times higher than the rate among native-born persons (2.7 per 100,000); foreign-born persons accounted for 53% of the 14,874 TB cases reported in the United States

This is the first large population-based epidemiologic study of TB in foreign-born persons in the United States and Canada. To prepare for the study, TBESC researchers developed and pilot-tested an hour-long questionnaire that asks participants about their socioeconomic status, immigration and travel history, history of TB symptoms and care sought for those symptoms, previous treatment and testing for TB, and knowledge and attitudes about TB. The questionnaire has been translated into 10 languages. It will be supplemented with clinical data on each participant that is routinely collected and reported to the CDC and Health Canada.

Researchers will enter the data into a Web-based data entry system developed for the study that can also be adapted to other TBESC studies. 

Data collection will be completed in 2006. These data will be used to identify interventions that can improve basic TB control activities and inform public health efforts to eliminate TB in the United States and Canada.

—Reported by Dolly Katz, PhD
Div of TB Elimination

Surveillance Team Update

The primary goal of the Surveillance Team is to maintain a high-quality National Tuberculosis Surveillance System and to enhance the dissemination and use of surveillance data in collaboration with health departments. Following is an update on some of the surveillance team’s current activities:

  • OTIS, the Online Tuberculosis Information System, is now online and available to the public. Users can request tabular counts and percentages for 22 selected RVCT variables and rates for national demographic data. The system can be accessed by going to http://wonder.cdc.gov/tb.html or at http://wonder.cdc.gov/, then selecting Online Tuberculosis Information System.
  • The National Surveillance System for Severe Adverse Events Associated with Treatment of Latent TB Infection is underway. DTBE urges health care providers and health departments to report all severe adverse events (e.g., liver injury, metabolic acidosis, anaphylaxis, seizure, severe dermatitis) leading to hospitalization or death of a person receiving any treatment for LTBI that occurred after January 1, 2004. Please report by telephone: 404-639-8401 or e-mail: LManangan@cdc.gov.
  • In conjunction with World TB Day on March 24, 2006, DTBE released an MMWR article on 2005 provisional surveillance data. The annual report, Reported Tuberculosis in the United States, 2005, with final 2005 data, will be ready for distribution in December 2006. DTBE is soliciting input on ways to enhance the dissemination and use of the surveillance report. Please send your suggestions to GNewell@cdc.gov.

—Reported by Lilia Manangan and Glenda Newell
Div of TB Elimination

 

Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

 

 
Back to Top of Page


If you would like to order any of the DTBE publications please visit the online order form.

You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: cdcinfo@cdc.gov


Skip Bottom Nav Home | Site Map | Contact Us
Accessibility | Privacy Policy Notice | FOIA | USA.gov
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: CDCINFO@cdc.gov